JCE BIOTECHNOLOGY : revenue, balance sheet and financial ratios

JCE BIOTECHNOLOGY is a French company founded 28 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in HAUTERIVE (03270), this company of category PME shows in 2024 a revenue of 18.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - JCE BIOTECHNOLOGY (SIREN 418489704)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 18 577 908 € 15 749 557 € 13 008 039 € 12 542 604 € 10 002 217 € 8 227 258 € 9 114 377 € 8 111 869 € 7 878 833 €
Net income 969 466 € 620 539 € 99 047 € 314 934 € 106 826 € -289 533 € 197 787 € 37 784 € 194 987 €
EBITDA 1 602 144 € 1 140 845 € 403 928 € 668 719 € 328 620 € -150 640 € 299 772 € 160 590 € 328 131 €
Net margin 5.2% 3.9% 0.8% 2.5% 1.1% -3.5% 2.2% 0.5% 2.5%

Revenue and income statement

In 2024, JCE BIOTECHNOLOGY achieves revenue of 18.6 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +11.3%. Vs 2023, growth of +18% (15.7 M€ -> 18.6 M€). After deducting consumption (8.0 M€), gross margin stands at 10.6 M€, i.e. a rate of 57%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.6 M€, representing 8.6% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 969 k€, i.e. 5.2% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

18 577 908 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

10 599 039 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

1 602 144 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

1 346 575 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

969 466 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

8.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 49%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 36%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.6 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 6.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

49.492%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

36.419%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

6.716%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

1.582

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

44.2%

Solvency indicators evolution
JCE BIOTECHNOLOGY

Sector positioning

Debt ratio
49.49 2024
2022
2023
2024
Q1: 1.92
Med: 18.86
Q3: 55.42
Average

In 2024, the debt ratio of JCE BIOTECHNOLOGY (49.49) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
36.42% 2024
2022
2023
2024
Q1: 24.8%
Med: 50.27%
Q3: 69.09%
Average

In 2024, the financial autonomy of JCE BIOTECHNOLOGY (36.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
1.58 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.3 years
Q3: 1.74 years
Average

In 2024, the repayment capacity of JCE BIOTECHNOLOGY (1.58) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 345.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 4.3x. Financial charges are adequately covered by operations.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

345.682

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

4.283

Liquidity indicators evolution
JCE BIOTECHNOLOGY

Sector positioning

Liquidity ratio
345.68 2024
2022
2023
2024
Q1: 159.64
Med: 253.69
Q3: 429.69
Good +33 pts over 3 years

In 2024, the liquidity ratio of JCE BIOTECHNOLOGY (345.68) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
4.28x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.67x
Q3: 4.96x
Good

In 2024, the interest coverage of JCE BIOTECHNOLOGY (4.3x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 78 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 45 days. The gap of 33 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 60 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 105 days of revenue, i.e. 5.4 M€ to permanently finance. Over 2016-2024, WCR increased by +111%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

5 434 781 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

78 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

45 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

60 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

105 j

WCR and payment terms evolution
JCE BIOTECHNOLOGY

Positioning of JCE BIOTECHNOLOGY in its sector

Comparison with sector Fabrication de matériel médico-chirurgical et dentaire

Valuation estimate

Based on 57 transactions of similar company sales (all years), the value of JCE BIOTECHNOLOGY is estimated at 3 888 789 € (range 1 124 494€ - 7 571 216€). With an EBITDA of 1 602 144€, the sector multiple of 2.5x is applied. The price/revenue ratio is 0.23x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
57 tx
1124k€ 3888k€ 7571k€
3 888 789 € Range: 1 124 494€ - 7 571 216€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
1 602 144 € × 2.5x
Estimation 4 068 421 €
799 593€ - 7 523 817€
Revenue Multiple 30%
18 577 908 € × 0.23x
Estimation 4 213 477 €
1 958 216€ - 8 815 986€
Net Income Multiple 20%
969 466 € × 3.0x
Estimation 2 952 684 €
686 166€ - 5 822 560€
How is this estimate calculated?

This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de matériel médico-chirurgical et dentaire)

Compare JCE BIOTECHNOLOGY with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire

Frequently asked questions about JCE BIOTECHNOLOGY

What is the revenue of JCE BIOTECHNOLOGY ?

The revenue of JCE BIOTECHNOLOGY in 2024 is 18.6 M€.

Is JCE BIOTECHNOLOGY profitable?

Yes, JCE BIOTECHNOLOGY generated a net profit of 969 k€ in 2024.

Where is the headquarters of JCE BIOTECHNOLOGY ?

The headquarters of JCE BIOTECHNOLOGY is located in HAUTERIVE (03270), in the department Allier.

Where to find the tax return of JCE BIOTECHNOLOGY ?

The tax return of JCE BIOTECHNOLOGY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does JCE BIOTECHNOLOGY operate?

JCE BIOTECHNOLOGY operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.